Newcomer Alexion Pharmaceuticals is claiming a neck-and-neck position in the race to meet human transplant demands with transgenic pig organs. Even as DNX Inc., a five-year veteran, last week unveiled a new strategy to complement its microinjection technique for inserting genetically engineered DNA into embryos, privately held Alexion, founded last year, announced the acquisition of technology that "leap-frogs" past the need for microinjection, according to the company's president and CEO, Leonard Bell. Both companies predict their first swine-to-human xenotransplants will take place mid-decade.